Pre-operative Investigations
Medicines and Consumables at the hospital
Food at the hospital
Airport transfers
IndiCure assistance

Does Not Include

Accommodation outside the hospital
Air tickets

Stay Required

Stay at the Hospital – 1 to 2 days   
Stay in India – 5 to 7 days

The cost quoted above is indicative and should not be taken as the final cost of the surgery. The final cost can be ascertained after the surgeon has evaluated the patient. The cost in Indian Rupees can vary based on exchange rate.

Lutetium PSMA Therapy Cost in India starts from US $ 6,000 and varies depending on your medical condition and history, comorbidities, if any, treating doctor, facility and the city where you choose to get the treatment done.

Factors that affect Lu (Lutetium) PSMA Therapy cost in India
  • Specialist’s Fees

    An important expense when it comes to your lutetium PSMA therapy is going to be your oncologist’s fees. IndiCure recommends highly experienced, skilled, board-certified doctors who are capable of delivering successful therapies. Although the charges may vary depending on the experience of the doctor, you can be assured that you are in safe and skilled hands when you choose cancer treatment in India with IndiCure.

  • Hospital Facility

    Having your lutetium PSMA therapy in an accredited facility by skilled and qualified medical staff is a critical factor. Moreover, the geographical location of this facility in India also affects the quote. But, IndiCure provides you with a projected estimate that will be all inclusive and affordable.

We at IndiCure, understand that you travel with a budget in mind and do not like to be greeted by surprises after arrival in India. We thus club all these expenses and give you the package cost that is inclusive and affordable at the same time.

Your case manager shall give you an estimated cost of your surgery after discussing your medical reports with the surgeon. The final cost, however, shall be confirmed after your consultation with the surgeon.

Making Medical Travel to India Affordable & Hasslefree for 10+ Years

Our services are FREE for our patients.

In fact, we have Special Negotiated Rates with the Hospitals and you can avail Discounted Rates when you choose to Travel with IndiCure.

IndiCure Services

We Help you Choose the Right Treatment, Surgeon & Hospital

We Arrange Video/Telephonic Consultation with the Surgeon

We Assist you with Visa & Accommodation

We Receive you at the Airport

We Assist you at Hospital & Provide Post Operative Support

Watch Our Patients Talk





Best Nuclear Medicine Surgeons in India

Dr IPS Oberoi
Dr. IPS Oberoi
MS (Orth.), MCh Orth. (Liverpool, U.K)
25+ Years of Experience

Dr. I P S Oberoi is an expert in Primary and Revision Joint replacement surgeries of Total Hip, Hip, Shoulder, Elbow, and Ankle joints.

Dr Mudit Khanna
Dr. Mudit Khanna
M.B.B.S, MS(Orthopedics)
21+ Years of Experience

Dr. Mudit Khanna is a Mumbai-based orthopedic surgeon who specializes in arthroplasty and arthroscopy.

Dr Yash Gulati
Dr. Yash Gulati
MBBS, MS (Ortho), M.Ch(Ortho), Eng
29+ Years of Experience

Dr. Yash Gulati was the first to introduce the concept of gyroscope-based computer navigation for Total Hip replacement in India.

Best Nuclear Medicine Hospitals in India

Wockhardt Hospital - mumbai
WockHardt Hospital


Wockhardt Hospitals is the branch of the leading Wockhardt pharmaceutical company in India. The company is more than four decades old and is present in more than 20 countries around the globe. Wockhardt has 9 hospitals in India in Mumbai, Nagpur, Rajkot, Nashik, and Surat.

Artemis Health Institute - Gurgaon
Artemis Hospital


Artemis Health Institute, a premium multi-specialty hospital is a healthcare venture launched by the promoters of the Apollo Tyres Group. Established in 2007, Artemis was the first hospital in Haryana to get NABH accreditation within 3 years of start-up.

See How It Works

What is Lutetium PSMA Therapy ?

PSMA (Prostate Specific Membrane Antigen) treatment with lutetium-177 is a type of radionuclide therapy used to kill prostate cancer cells that have migrated to other regions of the body, such as lymph nodes and bones. The eradication of prostate cancer cells may extend life expectancy and ease symptoms such as bone discomfort, which are commonly associated with cancer deposits in the skeleton.

Lutetium-177 is a radionuclide that produces harmful radiation that destroys neighboring cells. It’s coupled with a protein called PSMA, which looks for PSMA receptors on the majority of prostate cancer cell surfaces. Once administered into a patient’s bloodstream, Lutetium-177 PSMA will seek out and connect to PSMA receptors on prostate cancer cells. Prostate cancer cells will die over time as a result of the damaging radiation from Lutetium-177.

Lutetium PSMA therapy slows cancer cell proliferation, shrinks tumors, and, most importantly, improves patients’ quality of life by lowering cancer-related discomfort.

Read More

When is Lutetium PSMA Therapy required ?

Currently, Lutetium-177 PSMA is used in patients with metastatic prostate cancer who have failed other forms of treatment such as hormone therapy or chemotherapy. Before commencing treatment, patients will need to undergo a PSMA PET-CT scan to confirm PSMA receptors on the cancer cells, which will be targeted by Lutetium-177 PSMA.

How is Lutetium PSMA Therapy done?

Lutetium-177 PSMA is administered by injection into the bloodstream every 6-8 weeks. An intravenous line is established on the day of therapy, and the Lutetium-177 PSMA is infused over 30 minutes.

Antiemetics and a diuretic (to promote urine clearance) are also given at the same time. After 24-72 hours, a SPECT scan is performed to check that disease areas have been effectively targeted. The majority of individuals require four therapy cycles.

A repeat PSMA PET-CT is conducted after two cycles to assess therapy response. If the PSA levels have lowered and a repeat PSMA scan shows a good response, further two cycles will be given to complete the full treatment course of four cycles.

What Results Can I Expect from Lutetium PSMA Therapy?

Around 60-70 percent of patients who receive the treatment will have a positive reaction (e.g., symptom relief), and in some cases, it may result in a reasonably long-term illness remission. It is also possible to extend one’s life expectancy.

Questions to Ask

We at IndiCure completely understand your concerns and it is always our endeavor to provide the best outcome for every patient. Following is the list of questions you must ask before you embark on your journey for Lutetium PSMA Therapy in India.

  • How experienced is the Surgeon?
  • Which language does the surgeon speak?
  • Is the treatment done in a well-equipped facility?
  • What about the risks involved?

Preparation for the Surgery

Prepare to answer questions about your:

  • Medical history and exams
  • Previous surgeries
  • Current medication review
  • History of smoking, drugs, or alcohol

Patient Testimonials

Frequently Asked Questions

Lutetium-177 is a radioactive material that emits beta radiation, which is a type of radiation that is harmful to living things. Lutetium-177 is attached to a short peptide that binds to the PSMA receptor on the surface of cancer cells. When the Lutetium 177 – PSMA complex is coupled to a prostate cancer cell, it produces lethal radiation, causing the cancer cell to die. The surrounding normal cells are spared due to the low penetration of the released beta particle.

Lu177 PSMA is injected into the vein. The patient is admitted to the hospital and will be there for the next 24 hours. Prior to the Lu177 PSMA injection, a MAG3/EC scan is performed to assess kidney function.

Intravenous fluids are normally given to the patient before and after the Lu177 PSMA is given throughout a 24-hour period.

PSMA Lu177 is well tolerated. A little dry mouth, tiredness, and nausea are the most prevalent adverse effects. About 2–3 weeks following the Lu177 PSMA delivery, there may be a modest drop in white blood cells and platelets. These side effects are usually mild and transitory, and they go away on their own without any active therapy. Serious or life-threatening consequences are relatively uncommon.

Lu177 PSMA response rates are determined by the tumor biology of prostate cancer, the initial Gleason Score, the degree of illness, and prior therapy responses. Lu177 PSMA therapy typically results in a drop in S. PSA and a shrinking of tumors in more than 70% of patients. By the second dosage of therapy, nearly all patients have experienced a reduction in pain and an improvement in overall health.

Lu PSMA Therapy is a particularly precise therapy that is used to treat metastatic prostate cancer or when other methods of treatment are no longer effective. Patients with advanced castration-resistant metastatic prostate cancer who have shown indications of tumor progression are candidates for this treatment. The following symptoms may appear as cancer progresses:

  • Rising Serum PSA levels
  • Increase in the size or number of the metastatic lesions on CT/MRI or Ga68 PSMA scans
  • Increasing pain or other worsening symptoms due to the disease
  • Lu177 PSMA Therapy cannot be given to patients in case of Severe renal insufficiency
  • Severe hematological compromise

Add More to Your Medical trip